Table 5. Determination of sensitivity, specificity and accuracy of HA-family molecules for detecting BCa.
Sensitivity, specificity and accuracy of the biomarkers were determined using the cut-off values determined from the ROC curves. AUC: area under the curve. For all markers except CD44s, transcript levels ≥ cut-off value indicated a positive inference. For CD44s, the levels ≤ 0.026 indicated a positive inference (either true positive (i.e., BCa) or false positive). Six patients with prostate cancer were not included in the non-BCa category for specificity calculations. The mean and 95% CI for sensitivity, specificity and accuracy of each biomarker were computed by bootstrap modeling.
| Biomarker | AUC | Cut-off | Sensitivity (Mean; 95% CI) | Specificity | Accuracy |
|---|---|---|---|---|---|
| HAS1 | 0.80 | 4.0 | 72.9% (35/48) (77.85; 74.5 – 81.2) |
71.1% (59/83 68.5; 65.2 – 72) |
71.8% (94/131) 73.3; 72.4 – 74.1 |
| HAS2 | 0.86 | 6.6 | 72.9% (35/48) (67.0; 64.5 – 69.5) |
83.1% (69/83) (86.4; 84 – 88.8) |
79.4% (104/131) 76.7; 75.8 – 77.6 |
| HAS3 | 0.77 | 2.4 | 72.9% (35/48) (80.1; 77.6 – 82.5) |
74.7% (62/83) (66.6; 64 – 69.1) |
74.1% (97/131) 73.3; 72.4 – 74.1 |
| HYAL-1 | 0.83 | 6.6 | 72.9% (35/48) (68.5; 65.7 – 71.4) |
81.9% (68/83) (85.8; 83.2 – 88.3) |
78.6% (103/131 ) 77.2; 76.2 – 78.2 |
| HAS1-HYAL-1 | 0.85 | 5.0 | 77.1% (37/48) 75; 72.9 – 77.1 |
78.3% (65/83) 84.1; 82.3 – 85.9 |
77.9% (102/131) 79.6; 78.9 – 80.3 |
| HAS2-HYAL-1 | 0.89 | 5.2 | 85.4% (41/48) 83.8; 82.1 – 85.5 |
79.5% (66/83) 83.1; 81.5 – 84.7 |
81.7% (107/131) 83.4; 82.8 – 84.1 |
| HAS3-HYAL-1 | 0.84 | 5.7 | 70.8% (34/48) 76.9; 74.7 – 79.3 |
79.5% (66/83) 80.6; 78.4 – 82.8 |
76.3% (100/131) 78.8; 78.1 – 79.5 |
| HAS1-HAS2 | 0.87 | 6.1 | 75% (36/48) 77.1; 74.8 – 79.5 |
80.7% (67/83) 84.4; 82.3 – 86.6 |
78.6% (103/131) 80.8; 80.2 – 81.4 |
| HAS2-HAS3 | 0.85 | 7.1 | 87.5% (42/48) 85.2; 83.5 – 86.9 |
69.9% (58/83) 74.1; 72.4 – 75.8 |
76.3% (100/131) 79.7; 79.0 – 80.4 |
| HAS1-HAS3 | 0.81 | 4.1 | 75% (36/48) 85.2; 83.3 – 87.2 |
69.9% (58/83) 67.9; 65.7 – 70.2 |
71.8% (94/131) 76.6; 75.9 – 77.2 |
| RHAMM | 0.52 | 0.17 | 39.6% (19/48) 45.1; 41 – 49.3 |
78.3% (65/83) 75.3; 71.4 – 79.3 |
64.1% (84/131) 60.3; 59.3 – 61.2 |
| CD44S | 0.74 | 0.026 | 62.5% (30/48) 66.3; 63.4 – 69.2 |
73.5% (61/83) 80.8; 77.6 – 80.04 |
69.5% (91/131) 73.6; 72.5 – 74.6 |
| CD44v | 0.45 | 4.4 | 81.3% (39/48) 78.5; 73.8 – 82.3 |
26.5% (22/83) 40.9; 36.3 – 45.8 |
46.7% (61/130) 59.7; 58.9 – 60.5 |
| CD44v/CD44s | 0.7 | 223 | 64.5% (31/48) 74.3; 70.3 – 78.3 |
72.3% (60/83) 58.5; 52.4 – 64.7 |
69.5% (91/131) 66.4; 64.6 – 68.2 |